Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

onday, December 9, 5:00 pm CT, 393-394
  • Oral presentation: Myeloma: Therapy, excluding Transplantation II
  • Abstract # 687
  • Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates of MRD Negativity in Newly Diagnosed Multiple Myeloma (MM) Patients

    • Dr. Neha Korde, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 3:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients
    • Abstract # 538

    Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib, Lenalidomide, and Dexamethasone (CRd)

    • Dr. Manisha Bhutani, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 7:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Advances in Multiple Myeloma and Plasma Cell Leukemia
    • Abstract # 762

    Phase I/II Dose Expansion of a Multi-Center Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

    • Dr. Jatin Shah, The University of Texas MD Anderson Cancer Center
    • Monday, December 9, 5:45 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation II
    • Abstract # 690

    Carfilzomib, Rituximab and Dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based the
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.; Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
    2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
    3. Amgen Announces 2012 First Quarter Dividend
    4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
    5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
    6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
    7. Amgen to Acquire Micromet
    8. Amgen to Present at the Leerink Swann Global Healthcare Conference
    9. Amgen Announces 2012 Third Quarter Dividend
    10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
    11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
    (Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
    (Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
    (Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
    Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
    ... working with highly-concentrated, opaque, or solid samples ... cells, polymer films, or phosphors, front-face fluorescence ... qualitative fluorescence measurements. Highly concentrated and opaque ... complete attenuation of the beam. When measuring ...
    ... , ... , Fluorescence immunoassay is applied ... stimulation. Interference from other sample components is limited by use ... The detection system includes a T-format sampling module mounting two ...
    ... By Laura Gaidar, Kristin Prasauckas, , ... , PerkinElmer Life Sciences, Inc. ... , AlphaScreen technology is ... high throughput screening applications. PerkinElmer Life Sciences has developed two instruments for ...
    Cached Biology Technology:Immunoassay of Theophylline by fluorescence polarisation 2Immunoassay of Theophylline by fluorescence polarisation 3Immunoassay of Theophylline by fluorescence polarisation 4Immunoassay of Theophylline by fluorescence polarisation 5Immunoassay of Theophylline by fluorescence polarisation 6Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP 2Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP 3Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP 4
    (Date:4/23/2014)... turning away from using triclosan as an antimicrobial ingredient ... And now scientists are reporting new evidence that appears ... ACS journal Chemical Research in Toxicology , found ... octylphenol, promoted the growth of human breast cancer cells ... , Kyung-Chul Choi and colleagues note that hormonal imbalances ...
    (Date:4/23/2014)... date of the family of bacteria that causes ... and reveals surprising findings about the bacteria,s origin ... health strategies to control this respiratory disease, which ... analysis of 343 strains of the Bordetella ... over the last 100 years illustrates how vaccination ...
    (Date:4/23/2014)... April 23, 2014 A biomedical engineer at the ... innovative technology to make blood transfusions safer. His work ... National Institutes of Health (NIH). , Blood transfusions ... of modern medicine,s absolute necessities. Without them, for instance, ... transfusions are perfect, however. There,s strong evidence that transfusions ...
    Breaking Biology News(10 mins):In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Impact of whooping cough vaccination revealed 2UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3
    ...   According to a new market research ... - 2015) ", published by,MarketsandMarkets ... reach $3656.8 million by,2015 at a CAGR of 27.6% and ... 2015 at a CAGR of 25.6% ...
    ... , Like the vast African plains, two huge expanses of ... an array of marine predators in predictable seasonal patterns, according ... of Pacific Predators (TOPP) project published today in the ... decade-long effort to track top marine predator movements in the ...
    ... in the North Sea will promote fish stock recovery and ... the University of York., In the North Sea up to ... caught, with the result that many fisheries are now badly ... the late 1980s and their fisheries are now some of ...
    Cached Biology News:MarketsandMarkets: Global Touchless Sensing Market to be Worth $3656.8 Million and Global Gesture Recognition Market Worth $625 Million by 2015 2MarketsandMarkets: Global Touchless Sensing Market to be Worth $3656.8 Million and Global Gesture Recognition Market Worth $625 Million by 2015 3MarketsandMarkets: Global Touchless Sensing Market to be Worth $3656.8 Million and Global Gesture Recognition Market Worth $625 Million by 2015 4Teeming with life, Pacific's California current likened to Africa's Serengeti Plain 2Teeming with life, Pacific's California current likened to Africa's Serengeti Plain 3Teeming with life, Pacific's California current likened to Africa's Serengeti Plain 4Teeming with life, Pacific's California current likened to Africa's Serengeti Plain 5Discards ban 'will boost fisheries', says new research 2
    ... 2000 instrument can be used as a ... Data Manager Software provides the means to ... the instrument. These data can then be ... such as Microsoft Excel or Lotus 123, ...
    ... allows for quick and reproducible immunoprecipitation (IP) by ... is more reproducible than regular IPs, which are ... agarose without disrupting the agarose bed. The binding ... is reversible, and elution of the immune complex ...
    ... description: self locking design in ice/water ... new product number, created to easily ... no availability yet, please order under ... contact customer service for assistance. ID ...
    Kit containing MACS equipment and reagents for immunopurification of proteins....
    Biology Products: